Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expanded ...
When asked what Moleculent’s cell-cell interaction mapping technology provides to translational researchers, CEO Olle Ericsson explained that it adds “a new layer of information,” specifically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results